Skip to main content

Clinical Trials Using Durvalumab

Review the clinical trials studying durvalumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 87

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Status: Active
Location: 2 locations
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Durvalumab for the Treatment of Patients with Stage IA2-III Non-small Cell Lung Cancer who Have Minimal Residual Disease
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Immunotherapy with or without Radiation Therapy for the Treatment of Patients with Advanced Unresectable Intrahepatic Cholangiocarcinoma, a HYPERION CCA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Durvalumab and Stereotactic Ablative Radiotherapy for the Treatment of Advanced Non-small Cell Lung Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, DURVA+ Trial
Status: Active
Location: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
Tremelimumab and Durvalumab for the Treatment of Advanced Liver Cell Cancer in Patients with Child-Pugh-B Cirrhosis
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Pemigatinib and Durvalumab for the Treatment of FGFR2 Gene Fusion Positive or Rearranged Locally Advanced Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Location: 2 locations
Propranolol and Chemoradiation Therapy for the Treatment of Patients with Esophageal Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Y-90 SIRT in Combination with Durvalumab and Gemcitabine and Cisplatin for the Treatment of Locally Advanced, Unresectable, or Metastatic Biliary Tract Cancer
Status: Active
Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Preoperative Hypofractionated Radiotherapy with FOLFOX for the Treatment of Stage I-III Esophageal or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: 2 locations
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined with Immune Checkpoint Inhibition after High-Dose External Beam Radiation Therapy in Treating Patients with Unresectable Liver Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Risk-Adapted, Proteomic-Guided (PROphet CB, and CARG-TT) Systemic Therapy for the Treatment of Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Durvalumab and Tremelimumab with or without Chemotherapy for the Treatment of Potentially Resectable Pleural Mesothelioma
Status: Active
Location: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
NBTXR3, Radiation Therapy, and Immunotherapy (Anti-PD-1/L-1) for the Treatment of Lung and/or Liver or Soft Tissue Metastases from Solid Malignancy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
CTX-009, Gemcitabine, Cisplatin, and Durvalumab for the Treatment of Patients with Unresectable, Metastatic, or Recurrent Biliary Tract Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
DRP-104 in Combination with Durvalumab for the Treatment of Patients with Metastatic or Unresectable Fibrolamellar Hepatocellular Carcinoma
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Yttrium-90 Radioembolization in Combination with Tremelimumab and Durvalumab for Treating Patients with Locally Advanced, Unresectable or Oligo-metastatic Intrahepatic Cholangiocarcinoma Who are Not Candidates for Curative Therapy, RAIDEN Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
A Peptide Vaccine (mBTCvax) Plus Durvalumab and Tremelimumab for the Treatment of Biliary Tract Cancers
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Intravesical Romidepsin in Combination with Durvalumab for the Treatment of Localized Muscle Invasive Bladder Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Cryoablation and Hepatic Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab for the Treatment of Locally Advanced or Metastatic and/or Unresectable Liver cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination with Gemcitabine, Cisplatin and Durvalumab for the Treatment of Biliary Tract Cancer Patients with Peritoneal Metastases
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California